CCM
NVAX icon

Coldstream Capital Management’s Novavax NVAX Stock Holding History

Coldstream Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-266
Closed -$1.71K – 2578
2025
Q1 		$1.71K Buy
+266
New +$2.2K ﹤0.01% 3050
2017
Q2 		– Sell
-750
Closed -$19K – 282
2017
Q1 		$19K Hold
750
– – ﹤0.01% 252
2016
Q4 		$19K Hold
750
– – ﹤0.01% 235
2016
Q3 		$31K Buy
750
+60
+9% +$7.75K 0.01% 226
2016
Q2 		$100K Buy
690
+102
+17% +$11.7K 0.02% 219
2016
Q1 		$61K Buy
588
+50
+9% +$5.36K 0.01% 259
2015
Q4 		$90K Buy
+538
New +$82.8K 0.02% 196

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Coldstream Capital Management's NVAX Position: Q2 2025 in Review

Coldstream Capital Management sold out of Novavax (NVAX) in Q2 2025, closing a stake of 266 shares — an estimated $1.71K sold.

Coldstream Capital Management first reported a position in NVAX in Q4 2015 and held it in 7 quarters. The position peaked at $100K in Q2 2016. 250 funds tracked by Wall St. Rank hold NVAX as of Q2 2025.

  • Coldstream Capital Management reported no remaining Novavax position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 266 Novavax shares in Q2 2025, an estimated $1.71K.
  • Coldstream Capital Management first reported a position in Novavax in Q4 2015 and held it in 7 quarters.
  • Coldstream Capital Management's Novavax position peaked at $100K in Q2 2016.
  • 250 funds tracked by Wall St. Rank held Novavax as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.